首页> 美国卫生研究院文献>Journal of Translational Medicine >Optimal ex vivo expansion of neutrophils from PBSC CD34+ cells by a combination of SCF Flt3-L and G-CSF and its inhibition by further addition of TPO
【2h】

Optimal ex vivo expansion of neutrophils from PBSC CD34+ cells by a combination of SCF Flt3-L and G-CSF and its inhibition by further addition of TPO

机译:通过SCFFlt3-L和G-CSF的组合从PBSC CD34 +细胞中性粒细胞的最佳体外扩增及其通过进一步添加TPO的抑制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundAutologous mobilised peripheral blood stem cell (PBSC) transplantation is now a standard approach in the treatment of haematological diseases to reconstitute haematopoiesis following myeloablative chemotherapy. However, there remains a period of severe neutropenia and thrombocytopenia before haematopoietic reconstitution is achieved. Ex vivo expanded PBSC have been employed as an adjunct to unmanipulated HSC transplantation, but have tended to be produced using complex cytokine mixtures aimed at multilineage (neutrophil and megakaryocyte) progenitor expansion. These have been reported to reduce or abrogate neutropenia but have little major effect on thrombocytopenia. Selective megakaryocyte expansion has been to date ineffective in reducing thrombocytopenia. This study was implemented to evaluate neutrophil specific rather than multilineage ex vivo expansion of PBSC for specifically focusing on reduction or abrogation of neutropenia.
机译:背景自体动员外周血干细胞(PBSC)移植现在是血液学疾病治疗的标准方法,以重建清髓性化疗后的造血作用。然而,在造血重建之前,仍存在严重的中性粒细胞减少和血小板减少的时期。离体扩增的PBSC已被用作未进行HSC移植的辅助手段,但倾向于使用针对多谱系(中性粒细胞和巨核细胞)祖细胞扩增的复杂细胞因子混合物来生产。据报道,这些药物可减少或消除中性粒细胞减少症,但对血小板减少症的影响很小。迄今为止,选择性巨核细胞扩增在减少血小板减少症方面一直无效。进行这项研究是为了评估PBSC的嗜中性粒细胞特异性而不是多谱系离体扩增,从而特别着重于中性白细胞减少症的减少或消除。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号